Mclazide 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby reducing blood glucose levels. Mclazide 80 is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled by lifestyle modifications alone. The medication is typically administered once daily, preferably with breakfast, to optimize efficacy and minimize the risk of hypoglycemia. Gliclazide exhibits a selective action on pancreatic receptors, which contributes to a lower incidence of hypoglycemic episodes compared to other sulfonylureas. Patients should be monitored regularly for blood glucose levels, renal and hepatic function, and signs of hypoglycemia during therapy. Caution is advised in patients with impaired liver or kidney function, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Mclazide 80 should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance to achieve optimal glycemic control while minimizing side effects.